<p>Cognition Therapeutics, Inc. (NASDAQ: CGTX - 獲取免費報告) 在六月份的短期利空方面受到了大幅減少。截至 6 月 15 日，總共有 180,700 股的空頭頭寸，較 5 月 31 日的 210,600 股減少了 14.2%。公司約有 0.5% 的股份被賣空。基於平均交易量為 144,300 股，目前的空頭頭寸比率為 1.3 天。</p>
<p>獲取 <strong>Cognition Therapeutics</strong> 警報：</p>
<h2>Cognition Therapeutics 價格表現</h2>
<p>NASDAQ: CGTX 股票在週一交易中上漲了$0.01，達到$1.67。該股交易量為 79,644 股，相比平均交易量 177,680 股有所下降。該股的 50 天移動平均價為$2.02，200 天移動平均價為$2.01。Cognition Therapeutics 的一年最低價為$0.90，最高價為$2.95。該公司的市值為 6690 萬美元，市盈率為-1.82，貝塔係數為 1.48。</p>
<p>Cognition Therapeutics (NASDAQ: CGTX - 獲取免費報告) 最近發佈了其季度財報，日期為 5 月 7 日。公司報告該季度每股虧損 ($0.27)，低於市場預期的 ($0.23)。賣方分析師預測，Cognition Therapeutics 今年將發佈-0.97 美元的每股收益。</p>
<h2>分析師評級變動</h2>
<p>一些股票研究分析師最近對該公司發表了評論。B. Riley 在 3 月 28 日星期四重申了對 Cognition Therapeutics 股票的 “買入” 評級，並設定了$5.00 的目標價。Oppenheimer 在 3 月 27 日星期三重申了對 Cognition Therapeutics 股票的 “表現優異” 評級，並設定了$9.00 的價格目標。HC Wainwright 在 5 月 29 日星期三開始對 Cognition Therapeutics 股票進行覆蓋。他們給予該股 “買入” 評級，並設定了$10.00 的目標價。最後，Chardan Capital 在 6 月 6 日星期四對 Cognition Therapeutics 股票進行了覆蓋。他們給予該公司 “買入” 評級，並設定了$11.00 的價格目標。根據 MarketBeat 的數據，五位研究分析師對該股票給予買入評級。目前，市場普遍評級為 “買入”，平均目標價為$8.20。</p>
<p><strong>查看我們關於 CGTX 的最新股票報告</strong></p>
<h2>對 Cognition Therapeutics 的對沖基金看法</h2>
<p>大型投資者最近增加或減少了他們在該公司的持股。AWM Investment Company Inc.在第一季度購入了 Cognition Therapeutics 股票，價值約 118.3 萬美元。Hohimer Wealth Management LLC 在第一季度購入了 Cognition Therapeutics 的新頭寸，價值 41 萬美元。CM Management LLC 在第一季度購入了 Cognition Therapeutics 的新頭寸，價值 31.8 萬美元。Twin Focus Capital Partners LLC 在第四季度購入了 Cognition Therapeutics 股票，價值 17.3 萬美元。最後，Texas Capital Bank Wealth Management Services Inc.在第四季度購入了 Cognition Therapeutics 股票，價值約 10.2 萬美元。機構投資者持有該公司 43.35% 的股份。</p>
<h2>關於 Cognition Therapeutics（獲取免費報告）</h2>
<p>Cognition Therapeutics, Inc.是一家臨牀階段的生物製藥公司，致力於發現和開發針對年齡相關退行性疾病、中樞神經系統和視網膜疾病的小分子治療藥物。其主要產品候選藥物是 CT1812，一種口服分子調節劑，設計用於穿透血腦屏障並選擇性結合到 S2R 複合物，目前正在進行治療阿爾茨海默病的 2 期臨牀試驗，以及治療乾性老年性黃斑變性和α-突觸核病等疾病。</p>
<h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票比 Cognition Therapeutics 更好</li>
<li>股票交易：RSI 及其用途</li>
<li>這三家頂級銀行在通過聯邦壓力測試後提高了股息</li>
<li>交易停牌解釋</li>
<li>乘坐 Lyft 股票在下半年獲得兩位數增長</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>艾禮莉股票上漲：GLP-1 Zepbound 瞄準睡眠呼吸暫停市場</li>
</ul>
<p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或意見發送至 contact@marketbeat.com.</em></p>
<p>→ 喬·拜登剛剛透露了他的接班人？（來自 Paradigm Press）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg0"/></p>
<h2>您現在是否應該投資$1,000 在 Cognition Therapeutics？</h2>
<p>在考慮投資 Cognition Therapeutics 之前，您可能會想聽聽這個。</p>
<p>MarketBeat 追蹤華爾街頂級評級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Cognition Therapeutics 並不在名單上。</p>
<p>儘管 Cognition Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

CGTX

<p>Cognition Therapeutics, Inc.在六月份經歷了空頭頭寸的顯著下降，與上個月相比下降了 14.2%。該公司的股票目前被空頭賣出率為 0.5%，空頭頭寸比率為 1.3 天。該股的交易量和價格也一直在波動。分析師們給予該股票 “買入” 的共識評級，並設定了 8.20 美元的價格目標。機構投資者持有該公司股票的比例為 43.35%。Cognition Therapeutics 是一家專注於開發針對年齡相關性退行性疾病和中樞神經系統疾病的治療藥物的臨牀階段生物製藥公司</p>

<p>Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) was the recipient of a large drop in short interest in the month of June. As of June 15th, there was short interest totalling 180,700 shares, a drop of 14.2% from the May 31st total of 210,600 shares. Approximately 0.5% of the company's shares are sold short. Based on an average trading volume of 144,300 shares, the short-interest ratio is presently 1.3 days.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc. (NASDAQ: CGTX - 獲取免費報告) 在六月份的短期利空方面受到了大幅減少。截至 6 月 15 日，總共有 180,700 股的空頭頭寸，較 5 月 31 日的 210,600 股減少了 14.2%。公司約有 0.5% 的股份被賣空。基於平均交易量為 144,300 股，目前的空頭頭寸比率為 1.3 天。</p>
</div><p>Get <strong>Cognition Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Cognition Therapeutics</strong> 警報：</p>
</div><h2>Cognition Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Cognition Therapeutics 價格表現</h2>
</div><p>Shares of NASDAQ:CGTX traded up $0.01 during trading on Monday, reaching $1.67. 79,644 shares of the stock were exchanged, compared to its average volume of 177,680. The stock has a fifty day moving average of $2.02 and a two-hundred day moving average of $2.01. Cognition Therapeutics has a 1-year low of $0.90 and a 1-year high of $2.95. The firm has a market cap of $66.90 million, a price-to-earnings ratio of -1.82 and a beta of 1.48.</p>
<div class="lb-trans"><p>NASDAQ: CGTX 股票在週一交易中上漲了$0.01，達到$1.67。該股交易量為 79,644 股，相比平均交易量 177,680 股有所下降。該股的 50 天移動平均價為$2.02，200 天移動平均價為$2.01。Cognition Therapeutics 的一年最低價為$0.90，最高價為$2.95。該公司的市值為 6690 萬美元，市盈率為-1.82，貝塔係數為 1.48。</p>
</div><p>Cognition Therapeutics (NASDAQ:CGTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Sell-side analysts forecast that Cognition Therapeutics will post -0.97 EPS for the current year.</p>
<div class="lb-trans"><p>Cognition Therapeutics (NASDAQ: CGTX - 獲取免費報告) 最近發佈了其季度財報，日期為 5 月 7 日。公司報告該季度每股虧損 ($0.27)，低於市場預期的 ($0.23)。賣方分析師預測，Cognition Therapeutics 今年將發佈-0.97 美元的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several equities research analysts recently commented on the company. B. Riley restated a &#34;buy&#34; rating and set a $5.00 target price on shares of Cognition Therapeutics in a research report on Thursday, March 28th. Oppenheimer reaffirmed an &#34;outperform&#34; rating and set a $9.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday, March 27th. HC Wainwright initiated coverage on shares of Cognition Therapeutics in a research report on Wednesday, May 29th. They set a &#34;buy&#34; rating and a $10.00 target price on the stock. Finally, Chardan Capital assumed coverage on shares of Cognition Therapeutics in a report on Thursday, June 6th. They issued a &#34;buy&#34; rating and a $11.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $8.20.</p>
<div class="lb-trans"><p>一些股票研究分析師最近對該公司發表了評論。B. Riley 在 3 月 28 日星期四重申了對 Cognition Therapeutics 股票的 “買入” 評級，並設定了$5.00 的目標價。Oppenheimer 在 3 月 27 日星期三重申了對 Cognition Therapeutics 股票的 “表現優異” 評級，並設定了$9.00 的價格目標。HC Wainwright 在 5 月 29 日星期三開始對 Cognition Therapeutics 股票進行覆蓋。他們給予該股 “買入” 評級，並設定了$10.00 的目標價。最後，Chardan Capital 在 6 月 6 日星期四對 Cognition Therapeutics 股票進行了覆蓋。他們給予該公司 “買入” 評級，並設定了$11.00 的價格目標。根據 MarketBeat 的數據，五位研究分析師對該股票給予買入評級。目前，市場普遍評級為 “買入”，平均目標價為$8.20。</p>
</div><p><strong>Check Out Our Latest Stock Report on CGTX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 CGTX 的最新股票報告</strong></p>
</div><h2>Hedge Funds Weigh In On Cognition Therapeutics</h2>
<div class="lb-trans"><h2>對 Cognition Therapeutics 的對沖基金看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the business. AWM Investment Company Inc. purchased a new stake in shares of Cognition Therapeutics in the first quarter worth approximately $1,183,000. Hohimer Wealth Management LLC bought a new position in Cognition Therapeutics during the 1st quarter valued at $410,000. CM Management LLC purchased a new position in Cognition Therapeutics during the 1st quarter worth $318,000. Twin Focus Capital Partners LLC bought a new stake in shares of Cognition Therapeutics in the 4th quarter worth $173,000. Finally, Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $102,000. Institutional investors own 43.35% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近增加或減少了他們在該公司的持股。AWM Investment Company Inc.在第一季度購入了 Cognition Therapeutics 股票，價值約 118.3 萬美元。Hohimer Wealth Management LLC 在第一季度購入了 Cognition Therapeutics 的新頭寸，價值 41 萬美元。CM Management LLC 在第一季度購入了 Cognition Therapeutics 的新頭寸，價值 31.8 萬美元。Twin Focus Capital Partners LLC 在第四季度購入了 Cognition Therapeutics 股票，價值 17.3 萬美元。最後，Texas Capital Bank Wealth Management Services Inc.在第四季度購入了 Cognition Therapeutics 股票，價值約 10.2 萬美元。機構投資者持有該公司 43.35% 的股份。</p>
</div><h2>About Cognition Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>關於 Cognition Therapeutics（獲取免費報告）</h2>
</div><p>Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.</p>
<div class="lb-trans"><p>Cognition Therapeutics, Inc.是一家臨牀階段的生物製藥公司，致力於發現和開發針對年齡相關退行性疾病、中樞神經系統和視網膜疾病的小分子治療藥物。其主要產品候選藥物是 CT1812，一種口服分子調節劑，設計用於穿透血腦屏障並選擇性結合到 S2R 複合物，目前正在進行治療阿爾茨海默病的 2 期臨牀試驗，以及治療乾性老年性黃斑變性和α-突觸核病等疾病。</p>
</div><h2>Featured Articles</h2>
<ul>
<li>Five stocks we like better than Cognition Therapeutics</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>These Top 3 Banks Raise Dividends After Passing Fed Stress Test</li>
<li>Trading Halts Explained</li>
<li>Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half</li>
<li>What is the Australian Securities Exchange (ASX)</li>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><h2>精選文章</h2>
<ul>
<li>我們喜歡的五隻股票比 Cognition Therapeutics 更好</li>
<li>股票交易：RSI 及其用途</li>
<li>這三家頂級銀行在通過聯邦壓力測試後提高了股息</li>
<li>交易停牌解釋</li>
<li>乘坐 Lyft 股票在下半年獲得兩位數增長</li>
<li>什麼是澳大利亞證券交易所（ASX）</li>
<li>艾禮莉股票上漲：GLP-1 Zepbound 瞄準睡眠呼吸暫停市場</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由 Narrative Science 技術和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或意見發送至 contact@marketbeat.com.</em></p>
</div><p>→ Did Joe Biden just reveal his replacement? (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 喬·拜登剛剛透露了他的接班人？（來自 Paradigm Press）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTg0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8584&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Cognition Therapeutics right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資$1,000 在 Cognition Therapeutics？</h2>
</div><p>Before you consider Cognition Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Cognition Therapeutics 之前，您可能會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cognition Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂級評級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户在更廣泛市場注意之前現在購買的股票...而 Cognition Therapeutics 並不在名單上。</p>
</div><p>While Cognition Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Cognition Therapeutics 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Cognition Therapeutics 公司（納斯達克股票代碼：CGTX）空頭頭寸更新